ClinicalTrials.gg
CompletedNCT02178358Updated Feb 25, 2022Results posted

A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

A Phase 2 interventional study of LY2157299 and Sorafenib in Hepatocellular Carcinoma, sponsored by Eli Lilly and Company. Completed at 16 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-25.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 104 studies testing sorafenib in Carcinoma, Hepatocellular — 5 open to participants now, 7 under way, 1 of them phase 3. Sorafenib · Carcinoma, Hepatocellular.

Enrollment
25th of 104
132 · median 44
Started
2014
with 7 others
Phase 2
44 of 104
3 open now
Registered
78th of 104
by date

Among the 104 studies testing sorafenib in Carcinoma, Hepatocellular, this one is the 25th largest by enrollment, is one of 8 that started in 2014, is one of 44 in phase 2, and was the 78th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

5 of the 104 studies testing sorafenib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About sorafenib

Sorafenib: first FDA approval 2005 (NEXAVAR), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing sorafenib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2157299 in participants with hepatocellular carcinoma.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • transforming growth factor beta (TGF-β)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have histological evidence of a diagnosis of HCC not amenable to curative surgery.
  • Have Class A.
  • Have the presence of .
  • Have adequate organ function.
  • Have a performance status of ≤1 on the (ECOG) scale.
  • If male or female with , must agree to use medically approved precautions during the trial and for 3 months following the last dose of study drug.
  • If females with , must have had a negative serum pregnancy test 7 days prior to the first dose of study drug.
  • Are able to swallow capsules or tablets.
  • Have available diagnostic or tumor tissue.

Exclusion criteria

Exclusion Criteria:

  • Have received previous systemic treatment for advanced disease.
  • Have known HCC with fibro-lamellar or mixed histology.
  • Have presence of ascites.
  • Have had a liver transplant.
  • Have moderate or severe cardiac disease.
  • Have active or uncontrolled clinically serious virus or virus infection.
  • Have experienced Grade 3 or 4 gastrointestinal bleeding or any variceal bleeding episode in the 3 months prior to enrollment requiring transfusion or endoscopic or operative intervention.
  • Have esophageal or gastric varices that require immediate intervention or represent a high bleeding risk.
  • Had major surgery within 4 weeks prior to the study randomization.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    150 milligram (mg) Galunisertib Monotherapy

    150 mg galunisertib administered orally, twice daily (BID) for 14 days followed by 14 days with no study drug (28 days cycle).

    Drug: LY2157299

  • Experimental
    150 mg Galunisertib + 400 mg Sorafenib Therapy

    150 mg galunisertib administered orally, BID for 14 days followed by 14 days with no study drug (28 days cycle). 400 mg sorafenib administered orally BID for 28 days.

    Drug: LY2157299 · Drug: Sorafenib

  • Placebo comparator
    400 mg Sorafenib + Placebo Therapy

    Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 days cycle). 400 mg sorafenib administered orally BID for 28 days.

    Drug: Sorafenib · Drug: Placebo

Interventions

  • Administered orally

  • Administered orally

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS): Number of Events

    OS defined as the time from the date of randomization to the date of death due to any cause. An overall survival event was defined as death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive. The number of participants with overall survival events (deaths) is reported.

    Time frame: Randomization to Date of Death from Any Cause (Up To 24 Months)

Secondary outcomes

  1. Population Pharmacokinetics (PopPK): Mean Population Clearance of Galunisertib

    Population mean (between-subject coefficient variance \[CV %\]) apparent clearance.

    Time frame: Cycle (C) 1: Day (D)1: Predose, 0.5-2 hours(h) Postdose; D14: Predose, 0.5-2, 3-5 h, Postdose; D15 Morning; D22 Morning; Predose C2 and C3 Predose D1

  2. Population Pharmacokinetics (PopPK): Steady State Apparent Volume of Distribution (Vss) of Galunisertib

    Population Vss \[distribution of galunisertib in the body at steady state\] after a single dose of galunisertib.

    Time frame: Cycle (C) 1: Day (D)1: Predose, 0.5-2 hours(h) Postdose; D14: Predose, 0.5-2, 3-5 h, Postdose; D15 Morning; D22 Morning; Predose C2 and C3 Predose D1

  3. Time to Tumor Progression (TTP)

    TTP at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study, whichever came first. Progression was assessed by the Response Evaluation Criteria for Solid Tumors (RECIST) v1.1.Progressive Disease (PD)is at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

    Time frame: Randomization to the Date of Objective Progressive Disease or Date of Death due to Study Disease, whichever came first (Up To 24 Months)

  4. Progression-Free Survival (PFS)

    PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

    Time frame: Randomization to Measured Progressive Disease or Death (Up To 24 Months)

  5. Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

    ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.

    Time frame: Randomization to Measured Progressive Disease (Up To 24 Months)

  6. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Score

    EORTC QLQ-C30 consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much). 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.

    Time frame: Baseline, 24 Months

  7. Change From Baseline in EORTC QLQ Hepatocellular Carcinoma (HCC-18) Questionnaire Score

    The EORTC QLQ-HCC-18 was an 18-item questionnaire design used along with the 30-item EORTC QLQ-C30. EORTC QLQ-HCC 18 questionnaire included 8 symptom scales such as abdominal swelling, sex life, fatigue, body image, jaundice, nutrition, pain and fever. Each individual item ranges from 1 to 4, where 1 = "not at all" and 4 = "very much." All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a symptom scale/item represented a high level of symptomatology/problem.

    Time frame: Baseline, 24 Months

07

Results

Posted Dec 2, 2020

Participant flow

Participant flow — Overall Study
Milestone150 Milligram (mg) Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo Therapy
Started207438
Received at least 1 dose of study drug207438
Completed197236
Not completed122
Withdrew: Withdrawal by subject022
Withdrew: Lost to follow-up100

Outcome measures

PrimaryOverall Survival (OS): Number of Events

OS defined as the time from the date of randomization to the date of death due to any cause. An overall survival event was defined as death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive. The number of participants with overall survival events (deaths) is reported.

Time frame:
Randomization to Date of Death from Any Cause (Up To 24 Months)
Reported as:
Number · Participants with events
Overall Survival (OS): Number of Events
Participants with events150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo Therapy
Overall Survival (OS): Number of Events155831
Statistical analysis
  • 150 mg Galunisertib Monotherapy vs 400 mg Sorafenib + Placebo Therapy · Bayesian exponential-likelihood model · p = 0.837 · Hazard ratio (hr): 0.776 · 95% CI 0.434 to 1.226
  • 150 mg Galunisertib + 400 mg Sorafenib Therapy vs 400 mg Sorafenib + Placebo Therapy · Bayesian exponential-likelihood model · p = 0.704 · Hazard ratio (hr): 0.917 · 95% CI 0.633 to 1.266
SecondaryPopulation Pharmacokinetics (PopPK): Mean Population Clearance of Galunisertib

Population mean (between-subject coefficient variance \[CV %\]) apparent clearance.

Time frame:
Cycle (C) 1: Day (D)1: Predose, 0.5-2 hours(h) Postdose; D14: Predose, 0.5-2, 3-5 h, Postdose; D15 Morning; D22 Morning; Predose C2 and C3 Predose D1
Reported as:
Geometric mean · Liter per hour (L/hr)
Population Pharmacokinetics (PopPK): Mean Population Clearance of Galunisertib
Liter per hour (L/hr)Galunisertib Monotherapy and Galunisertib + Sorafenib Therapy
Population Pharmacokinetics (PopPK): Mean Population Clearance of Galunisertib33.6 ± 48
SecondaryPopulation Pharmacokinetics (PopPK): Steady State Apparent Volume of Distribution (Vss) of Galunisertib

Population Vss \[distribution of galunisertib in the body at steady state\] after a single dose of galunisertib.

Time frame:
Cycle (C) 1: Day (D)1: Predose, 0.5-2 hours(h) Postdose; D14: Predose, 0.5-2, 3-5 h, Postdose; D15 Morning; D22 Morning; Predose C2 and C3 Predose D1
Reported as:
Geometric mean · Liters (L)
Population Pharmacokinetics (PopPK): Steady State Apparent Volume of Distribution (Vss) of Galunisertib
Liters (L)Galunisertib Monotherapy and Galunisertib + Sorafenib Therapy
Population Pharmacokinetics (PopPK): Steady State Apparent Volume of Distribution (Vss) of Galunisertib192 ± 69
SecondaryTime to Tumor Progression (TTP)

TTP at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study, whichever came first. Progression was assessed by the Response Evaluation Criteria for Solid Tumors (RECIST) v1.1.Progressive Disease (PD)is at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Time frame:
Randomization to the Date of Objective Progressive Disease or Date of Death due to Study Disease, whichever came first (Up To 24 Months)
Reported as:
Median · Months
Time to Tumor Progression (TTP)
Months150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo Therapy
Time to Tumor Progression (TTP)1.41 (1.38 to 2.76)2.86 (2.63 to 4.21)4.14 (2.76 to 8.21)
SecondaryProgression-Free Survival (PFS)

PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

Time frame:
Randomization to Measured Progressive Disease or Death (Up To 24 Months)
Reported as:
Median · Months
Progression-Free Survival (PFS)
Months150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo Therapy
Progression-Free Survival (PFS)1.41 (1.38 to 2.76)2.86 (2.63 to 4.07)4.14 (2.76 to 5.59)
SecondaryPercentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.

Time frame:
Randomization to Measured Progressive Disease (Up To 24 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
Percentage of participants150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo Therapy
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])0.05 (0.001 to 0.249)0.027 (0.003 to 0.094)0.158 (0.060 to 0.313)
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Score

EORTC QLQ-C30 consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much). 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.

Time frame:
Baseline, 24 Months
Reported as:
Mean · units on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Score
units on a scale150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo Therapy
Global health status43.42 ± 23.17155.90 ± 22.47358.57 ± 17.326
Functional scale: Physical functioning84.56 ± 16.33882.87 ± 19.61380.95 ± 16.580
Functional scale: Role functioning89.47 ± 14.91882.05 ± 24.88085.24 ± 19.289
Functional Scale: Emotional Functioning84.65 ± 18.27187.18 ± 17.24786.90 ± 13.898
Functional Scale: Cognitive Functioning89.47 ± 16.86091.03 ± 14.75485.71 ± 18.142
Functional Scale: Social Functioning83.33 ± 24.84584.10 ± 19.85984.29 ± 18.052
Symptom Scale: Fatigue21.05 ± 23.39324.10 ± 22.44425.40 ± 18.390
Symptom Scale: Nausea and Vomiting2.63 ± 8.3583.85 ± 8.7253.33 ± 8.856
Symptom scale: Pain17.54 ± 19.62117.18 ± 25.34014.76 ± 20.521
Symptom scale: Dyspnoea17.54 ± 28.04011.79 ± 19.92212.38 ± 18.232
Symptom scale: Insomnia21.05 ± 31.8389.74 ± 19.29616.19 ± 16.903
Symptom scale: Appetite loss15.79 ± 25.74416.92 ± 25.76818.10 ± 23.351
Symptom scale: Constipation5.26 ± 12.4886.15 ± 13.0336.67 ± 15.760
Symptom scale: Diarrhoea10.53 ± 19.4134.62 ± 13.01310.48 ± 17.660
Symptom scale: Financial difficulties15.79 ± 25.74423.08 ± 26.95420.95 ± 22.989
SecondaryChange From Baseline in EORTC QLQ Hepatocellular Carcinoma (HCC-18) Questionnaire Score

The EORTC QLQ-HCC-18 was an 18-item questionnaire design used along with the 30-item EORTC QLQ-C30. EORTC QLQ-HCC 18 questionnaire included 8 symptom scales such as abdominal swelling, sex life, fatigue, body image, jaundice, nutrition, pain and fever. Each individual item ranges from 1 to 4, where 1 = "not at all" and 4 = "very much." All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a symptom scale/item represented a high level of symptomatology/problem.

Time frame:
Baseline, 24 Months
Reported as:
Mean · units on a scale
Change From Baseline in EORTC QLQ Hepatocellular Carcinoma (HCC-18) Questionnaire Score
units on a scale150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo Therapy
Abdominal swelling24.56 ± 33.04032.82 ± 31.45327.62 ± 24.899
Sex Life28.07 ± 31.94058.97 ± 35.24246.08 ± 35.783
Fatigue32.16 ± 21.56347.86 ± 29.12846.98 ± 26.278
Body Image28.07 ± 26.08936.15 ± 22.93031.90 ± 20.758
Jaundice20.18 ± 25.20227.69 ± 25.39225.24 ± 21.531
Nutrition22.46 ± 21.22334.05 ± 23.45634.48 ± 18.611
Pain25.44 ± 18.73225.38 ± 21.47130.95 ± 21.822
Fever14.04 ± 16.90925.38 ± 25.01920.48 ± 20.646

Adverse events

Collected over Up To 63 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
150 mg Galunisertib Monotherapy15/20 (75%)6/20 (30%)17/20 (85%)
150 mg Galunisertib + 400 mg Sorafenib Therapy58/74 (78.4%)31/74 (41.9%)73/74 (98.6%)
400 mg Sorafenib + Placebo Therapy31/38 (81.6%)11/38 (28.9%)38/38 (100%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
Event150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo Therapy
Upper gastrointestinal haemorrhageGastrointestinal disorders0/204/740/38
PyrexiaGeneral disorders0/204/740/38
Abdominal painGastrointestinal disorders0/203/742/38
Hearing impairedEar and labyrinth disorders1/200/740/38
Haemorrhoidal haemorrhageGastrointestinal disorders1/200/740/38
Oesophageal varices haemorrhageGastrointestinal disorders1/203/740/38
JaundiceHepatobiliary disorders1/200/740/38
PneumoniaInfections and infestations1/201/741/38
SepsisInfections and infestations1/200/740/38
HypoglycaemiaMetabolism and nutrition disorders1/200/740/38
Most frequent other events
Showing 10 of 79
Most frequent other events
Event150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo Therapy
DiarrhoeaGastrointestinal disorders5/2029/7422/38
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders4/2042/7419/38
HypophosphataemiaMetabolism and nutrition disorders2/2033/7413/38
Alanine aminotransferase increasedInvestigations2/2023/7415/38
Aspartate aminotransferase increasedInvestigations2/2026/7415/38
Blood bilirubin increasedInvestigations2/2011/7415/38
FatigueGeneral disorders6/2023/7414/38
Decreased appetiteMetabolism and nutrition disorders3/2027/7412/38
PyrexiaGeneral disorders1/2026/745/38
Platelet count decreasedInvestigations0/2019/7413/38

Baseline characteristics

All randomized participants.

Age, Categorical
Age, Categorical(Participants)150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo TherapyTotal
<=18 years0000
Between 18 and 65 years13552896
>=65 years7191036
Age, Continuous
Age, Continuous(years)150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo TherapyTotal
Mean60.6 ± 7.859.0 ± 8.558.6 ± 11.859.1 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo TherapyTotal
Female412117
Male166237115
Race (NIH/OMB)
Race (NIH/OMB)(Participants)150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo TherapyTotal
American Indian or Alaska Native0000
Asian207438132
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo TherapyTotal
South Korea7331353
Hong Kong610622
China015823
Taiwan711927
Thailand0527
Weight
Weight(kilogram (kg))150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo TherapyTotal
Median66.400 (40.00 to 83.20)63.575 (39.70 to 87.00)62.400 (51.10 to 82.15)63.575 (39.70 to 87.00)
Height
Height(Centimeter (cm))150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo TherapyTotal
Mean162.84 ± 7.38165.30 ± 7.50166.55 ± 5.69165.29 ± 7.05
BMI
BMI(kilogram per square metre (kg/m2))150 mg Galunisertib Monotherapy150 mg Galunisertib + 400 mg Sorafenib Therapy400 mg Sorafenib + Placebo TherapyTotal
Mean24.806 ± 4.10523.224 ± 3.24822.843 ± 3.06223.354 ± 3.373

3 further baseline measures are reported on the registry.

08

Study locations

16 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100036, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bengbu, 233004, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changchun, 130012, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hangzhou, 310016, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hefei, 230022, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hong Kong, Hong Kong
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kowloon, Hong Kong
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Incheon, 405-760, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 135 720, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gwei Shan Township, 333, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Liouying/Tainan, 736, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Puzih City, 613, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tainan, 70403, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 11217, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taoyuan, 33378, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangkok, 10330, Thailand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and european union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Jun 2017, 34 months.

Results were first posted in Dec 2020, 3 years 5 months after primary completion. A results delay was requested in Jun 2018.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 34 months is below that.

Counting every sponsor, half of 428 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2014
First posted
Jun 30, 2014
StartActual
Aug 8, 2014
Primary completionActual
Jun 30, 2017
CompletionActual
Feb 18, 2021
Results delay requested
Jun 5, 2018
Results first posted
Dec 2, 2020
Last update
Feb 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02178358
Responsible party
Sponsor
First posted
Jun 30, 2014
Start date
Aug 8, 2014
Primary completion
Jun 30, 2017
Completion
Feb 18, 2021
Results posted
Dec 2, 2020
Last update
Feb 25, 2022

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: LY-2157299 · Sorafenib

Start the discussion